Can a cancer drug help CIDP patients ditch their meds?
NCT ID NCT04480450
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study planned to test the drug rituximab in people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition that causes weakness and numbness. The goal was to see if rituximab could help certain patients stop their current treatments and achieve long-term remission. However, the study was withdrawn before any participants were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rituximab (a drug that depletes B cells, a type of immune cell)
What this could lead to
If successful, this study could identify which CIDP patients might achieve long-term remission and stop their current medications after rituximab treatment.
What could go wrong
This trial was withdrawn before enrolling any participants, so no results are available. It is a small, early-phase study, and it is unclear if rituximab will work for CIDP beyond a specific subgroup.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.